Stallergenes S.A.

Other News To Note.
BIOWORLD Today; 11/3/2009; 2419 words; ...launched Macugen in the U.S. Jan. 20. Shares of Eyetech...that Prestara, the company's investigational drug for lupus...the FDA to determine Prestara's future development. Shares of...agreed to collaborate with Stallergenes SA, of Antony, France, on...

STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial.(Clinical report)
Clinical Trials Week; 9/28/2009; 946 words; Stallergenes S.A. has announced the first results...allergen as an active substance. To Stallergenes' knowledge, the use of a recombinant...dosages. "This study conducted by Stallergenes marks a very important milestone in...

STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen rBet v 1 of Birch Pollen: Positive Results for a Phase IIb/III Trial.(Clinical report)
Clinical Trials Week; 9/28/2009; 1008 words; Stallergenes S.A. has announced the first results...of this pollen, rBet v 1 (see also Stallergenes). This study is the first ever to...allergen as an active substance. To Stallergenes' knowledge, the use of a recombinant...

Clinic Roundup.
BIOWORLD Today; 9/17/2009; 903 words; ...0.0001). Furthermore, that group's improvement was statistically significantly...patients with advanced non-Hodgkin's lymphoma that had returned or was not responding...percent of the control group patients. Stallergenes SA, of Antony, France, reported positive...

STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial.
PR Newswire; 9/16/2009; 1420 words; ...PRNewswire-FirstCall/ -- Stallergenes S.A. has announced the first...allergen as an active substance. To Stallergenes' knowledge, the use of a recombinant...dosages. "This study conducted by Stallergenes marks a very important milestone...